Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK2 | P24941 | 1/20 | 0.36 |
| ▸ | RET | P07949 | 1/20 | 0.34 |
| ▸ | PLAU | P00749 | 2/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5641945 | 1.00 | CDK2 (0.36) | CDK2RETPLAUKDM4EL3MBTL1 | |
| SCHEMBL376750 | 0.81 | ALDH1A1 (0.31) | CDK2KDM4EL3MBTL1 | |
| SCHEMBL376749 | 0.81 | ALDH1A1 (0.31) | CDK2KDM4EL3MBTL1 | |
| SCHEMBL5642472 | 0.75 | PLAU (0.34) | PLAU | |
| SCHEMBL5642479 | 0.75 | PLAU (0.34) | PLAU | |
| SCHEMBL3918346 | 0.70 | PKM (0.35) | KDM4EL3MBTL1 | |
| SCHEMBL3918342 | 0.70 | PKM (0.35) | KDM4EL3MBTL1 | |
| SCHEMBL10990986 | 0.68 | RET (0.31) | RET | |
| SCHEMBL10990984 | 0.68 | RET (0.31) | RET | |
| SCHEMBL8257576 | 0.68 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7163939-B2 | Macrocyclic kinase inhibitors | ABBOTT LABORATORIES (US) | 2007-01-16 | — | — | US | disclosed |
| EP-1682555-A1 | MACROCYCLIC KINASE INHIBITORS | ABBOTT LABORATORIES (US) | 2006-07-26 | — | — | EP | disclosed |
| US-20050215556-A1 | Macrocyclic kinase inhibitors | ABBVIE INC. | 2005-09-29 | — | — | US | disclosed |
| WO-2005047294-A1 | MACROCYCLIC KINASE INHIBITORS | ABBOTT LABORATORIES (US) | 2005-05-26 | — | — | WO | disclosed |
| US-20050096324-A1 | Macrocyclic kinase inhibitors | ABBOTT LABORATORIES | 2005-05-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050096324-A1 | Macrocyclic kinase inhibitors | MAP3K20, MAP3K19, MAP3K7 | CDK2 22/4885RET 438/4885PLAU 1868/4885 |
| US-20050215556-A1 | Macrocyclic kinase inhibitors | MAP3K20, MAP3K19, MAP3K7 | CDK2 22/4885RET 438/4885PLAU 1868/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.